Impact on risk stratification of overlap syndrome phenotype (Brugada and Long QT type 3) in patients with E1784K mutation in SCN5A
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
Risk stratification of patients with the SCN5A-E1784K mutation is challenging because they can express Brugada syndrome, long QT syndrome (LQTS), or both phenotypes (overlap syndrome). This study compared arrhythmic risk in patients with overlap syndrome versus single phenotype presentations.
Methods
We retrospectively enrolled patients aged 12 and older carrying the SCN5A-E1784K mutation. The primary outcome was major cardiac events (MCEs) defined as sustained ventricular arrhythmia, cardiopulmonary arrest and sudden cardiac death. Comparisons were made between patients expressing single phenotype (Brugada syndrome or LQTS type 3) and overlap syndrome.
Results
Forty-seven patients were enrolled (32 overlap group, 15 single phenotype group). MCE occurrence was 25% (8/32) in the overlap group and 6.7% (1/15) in the single phenotype group. Median follow-up was 156 months (single phenotype) and 127 months (overlap group). Despite a trend toward higher risk, comparison showed no statistically significant difference (OR 4.67, 95% CI: 0.53-41.4, p=0.275). Ajmaline testing reclassified 12% of patients, highlighting the importance of comprehensive diagnostic evaluation.
Conclusion
This study describes the largest cohort of SCN5A-E1784K mutation carriers reported. Although not statistically significant due to event rarity and sample size, results reveal a clear trend toward higher MCE prevalence in the overlap group. Ajmaline testing revealed underdiagnosis of overlap syndrome. Larger studies are needed for definitive conclusions.
